Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
44.21
+5.37 (13.83%)
At close: Sep 5, 2025, 4:00 PM
41.80
-2.41 (-5.45%)
After-hours: Sep 5, 2025, 7:57 PM EDT
Monopar Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Monopar Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $66.56, which forecasts a 50.55% increase in the stock price over the next year. The lowest target is $40 and the highest is $80.
Price Target: $66.56 (+50.55%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 5 |
| Buy | 2 | 2 | 2 | 3 | 3 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 8 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +80.95% | Sep 3, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $77 | Buy | Initiates | $77 | +74.17% | Sep 3, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $74 | Buy | Reiterates | $74 | +67.38% | Aug 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $70 | Strong Buy | Initiates | $70 | +58.34% | Aug 26, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +35.72% | Aug 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
969.00K
EPS This Year
-1.84
from -4.11
EPS Next Year
-3.70
from -1.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 4.0M | |||
| Avg | n/a | 969,000 | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.60 | -2.00 | |||
| Avg | -1.84 | -3.70 | |||
| Low | -2.28 | -5.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.